Plain-English translation of NCT05409482 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is observing how well two medications—camrelizumab and apatinib mesylate—work when used together to treat advanced liver cancer that cannot be surgically removed. Doctors and researchers want to understand how effective this treatment combination is in real-world settings, and whether it helps patients live longer with fewer side effects. The study will follow 300 patients over time to gather this information.
Liver cancer is difficult to treat, especially when it has spread and cannot be removed with surgery. Recent advances in immunotherapy and targeted medicines have shown promise in improving survival, but doctors need real-world data to understand which treatment combinations work best for patients like you.
You likely qualify if…
You likely don't qualify if…
This is an observational study, meaning you will receive the treatment as prescribed by your doctor—you won't be randomly assigned to different groups. Researchers will track your medical records, imaging scans, and clinical outcomes over time to see how well the medication combination works and what side effects you experience. You'll have routine hospital visits for treatment and monitoring, and the study team will follow up with you regularly to understand your progress and quality of life.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Collaborators
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Enrollment target
~300 participants
Started
August 2022
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yong yi Zeng
Mengchao Hepatobiliary Hospital, Fujian Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.